Literature DB >> 1671326

Lack of evidence for beta-2 receptor selectivity: a study of metaproterenol, fenoterol, isoproterenol, and epinephrine in patients with asthma.

C D Burgess1, H H Windom, N Pearce, S Marshall, R Beasley, R W Siebers, J Crane.   

Abstract

In order to investigate the pharmacodynamic selectivity of a number of beta-receptor agonists currently used in asthma, we compared the pulmonary and extrapulmonary effects of repeated inhalations of epinephrine, fenoterol, isoproterenol, and metaproterenol in 12 patients with asthma in a randomized double-blind crossover study. The drugs were administered from metered-dose inhalers at 15-min intervals for five doses (total dose, 10 puffs of each compound). Measurements of heart rate, blood pressure, total electromechanical systole (as a measure of inotropic response), QTc interval, plasma potassium, and FEV1 were made 5 min after each dose and 30 min after the final dose. Fenoterol and metaproterenol had significantly greater inotropic, electrocardiographic, chronotropic, and hypokalemic effects than did both isoproterenol and epinephrine. There was no difference in the bronchodilating effect of metaproterenol, fenoterol, or isoproterenol although these agents caused a significantly greater increase in FEV1 than did epinephrine. The concept of increasing beta-2 selectivity for metaproterenol and fenoterol compared with isoproterenol are not supported in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671326     DOI: 10.1164/ajrccm/143.2.444

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.

Authors:  J A Bennett; A E Tattersfield
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

2.  Cardiovascular effects of fenoterol under conditions of hypoxaemia.

Authors:  P Bremner; C D Burgess; J Crane; D McHaffie; D Galletly; N Pearce; K Woodman; R Beasley
Journal:  Thorax       Date:  1992-10       Impact factor: 9.139

Review 3.  Regular treatment with salmeterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

Review 4.  Regular treatment with formoterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 5.  Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

6.  Relative myotoxic and haemodynamic effects of the beta-agonists fenoterol and clenbuterol measured in conscious unrestrained rats.

Authors:  Jatin G Burniston; Lip-Bun Tan; David F Goldspink
Journal:  Exp Physiol       Date:  2006-09-14       Impact factor: 2.969

7.  Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.

Authors:  Orlagh O'Shea; Elizabeth Stovold; Christopher J Cates
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

8.  Inhaled steroids with and without regular salmeterol for asthma: serious adverse events.

Authors:  Christopher J Cates; Stefanie Schmidt; Montse Ferrer; Ben Sayer; Samuel Waterson
Journal:  Cochrane Database Syst Rev       Date:  2018-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.